Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

An editorial published in the New England Journal of Medicine 1 referred to the Photovoltaic Retina Implant Microarray (PRIMA ...

Rayner's Sophi Phacoemulsification System, cleared by the FDA, is now available to US cataract surgeons, enhancing surgical ...

Panelists discuss how emerging therapies—including TKIs, sustained-release implants, and gene therapy—may reduce treatment ...

EDOF technology, previously used in intraocular lenses, is now available in contact lenses, offering significant improvements ...

The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug ...

Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...

“The non-invasive in vivo optical imaging of rhodopsin activation extends the diagnostic capability of ORG and may facilitate ...

SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...

Ollin Biosciences has announced positive topline results from its randomized, head-to-head Phase 1b JADE clinical study ...